News

London-based infectious disease pharmaceutical company, Poolbeg Pharma, has announced their deal with testing and support specialist, Eurofins Genomics, according to Proactive Investors.

A chemotherapy drug, NUC-7738, which is derived from a Himalayan fungus has been found to have 40 times greater potency in killing cancer cells than its original parent compound.

Leading RNA intereference (RNAi) therapeutics company, Alnylam, has been welcomed as the latest partner in the Medicines Manufacturing Innovation Centre, to transform the manufacturing process of oligonucleotide therapies.

AstraZeneca has submitted an emergency approval to the US drug regulators for its COVID-19 antibody cocktail, which would be the first non-vaccine protection from the virus to be granted approval.

The UK’s first ‘asthma bus’ is set to begin its journey around the country, aiming to offer crucial support to pressured NHS respiratory services, as asthma sufferers have admitted to delaying care during the pandemic to avoid the risk of catching COVID-19.

UK-based Scancell Holdings has announced that its first subject has been dosed in its COVIDITY clinical trial in South Africa.

Pfizer and BioNTech have announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the administration of the Pfizer-BioNTech COVID-19 vaccine as a booster shot six months after the second dose.

Private biopharmaceutical research, development, and commercialisation company, AiPharma, has announced a strategic alliance with biopharmaceutical company Appili Therapeutics Inc (Appili), to advance the global development of Avigan®/Reeqonus™ (favipiravir).

The UK’s largest laboratory diagnostics company, Randox, has announced a nationwide expansion of ten new adaptive ‘cube’ laboratories across Great Britain, with facilities that provide a rapid and cost-effective model to expand laboratory provision.

MSD and Ridgeback Therapeutics announced that their investigational anti-viral medicine reduced the risk of hospitalisation and death by approximately 50% in non-hospitalised adult patients with mild-to-moderate COVID-19.

The European Patent Office (EPO) has granted a patent to specialist pharmaceutical company, N4 Pharma, for its Nuvec cancer treatment and vaccine delivery system.

The interim results from Aberdeen-born 4D Pharma revealed that the first half of 2021 was a “significant period” for the biotechnology firm, according Proactive.

People with advanced or metastatic urothelial cancer will soon have access to a new treatment option following a NICE recommendation.